Layoffs
Sanofi has announced major restructuring, which will involve layoffs.
The cuts are being made as the company grapples with a debt of between $30 and $35B and a restructuring of its R&D in order to combat dramatically declining revenue from its generic pipeline.
This Latest move is a wide-ranging effort to boost competitiveness.
Almost one year after filing a NDA for an ADHD drug and less than one year after announcing it secured $200M in financing, Ironshore Pharma has closed its doors.
Changes are coming to Medtronic.
GlaxoSmithKline CEO Emma Walmsley is not done reshaping her leadership team as she continues to overhaul the company’s pharmaceutical division.
Cellectar Biosciences is closing its manufacturing operations and contracting them out.
As a result, the company will cut 300 jobs, primarily in Massachusetts and Connecticut.
Not only has the company made changes to its R&D division, it is strengthening its sales division as well.
About 200 of the job cuts will be in Massachusetts, the remaining in Connecticut.
PRESS RELEASES
